One of the most striking revelations centers on the impact of sickle cell disease (SCD) on immune suppression and consequent immunotherapy resistance. SCD, primarily recognized as a hereditary red blood cell disorder, has now been implicated in altering the epigenetic and structural dynamics of immune cells, particularly CD8+ T lymphocytes. By leveraging advanced genomic and epigenomic techniques, investigators led by Drs. Pavlos Msaouel, Liuqing Yang, and Chunru Lin discovered that SCD induces a reconfiguration of chromatin architecture within CD8+ T cells. This remodeling suppresses genes essential for ferroptosis, an iron-dependent form of regulated cell death integral to immune cell function and tumor suppression. The silencing of this pathway leads to diminished production of hydrogen sulfide (H₂S), a gaseous signaling molecule that modulates immune responses. Intriguingly, therapeutic restoration of H₂S levels revived immune functionality in preclinical melanoma, breast, and kidney cancer models, charting a novel avenue to enhance the efficacy of immunotherapeutic interventions in patients compromised by SCD.

Exploring the realm of advanced prostate cancer, another research team led by Drs. Feiyu Chen and Di Zhao employed multi-omics strategies and sophisticated genetic modeling to unravel mechanisms underpinning castration-resistant prostate cancer (CRPC). This lethal variant of prostate cancer notoriously evades hormone-deprivation therapies due to its metabolic plasticity. The team identified that concurrent alterations in the chromatin remodeler gene CHD1 and the ubiquitin ligase SPOP facilitate a metabolic rewiring characterized by heightened cholesterol biosynthesis. Remarkably, this surge empowers tumor cells to synthesize androgens autonomously, thus circumventing standard anti-androgen regimens. Harnessing this mechanistic insight, the researchers demonstrated that a combinatory approach utilizing FDA-approved cholesterol-lowering agents alongside anti-androgen drugs elicited sustained tumor regression in preclinical models. This paves the way for biomarker-driven personalized therapies catered to genetically defined CRPC subsets.

The insidious propensity of cancers to metastasize to bone remains a formidable clinical hurdle, often conferring significant morbidity and poor patient survival. Addressing this challenge, Dr. Li Ma and colleagues employed in vivo CRISPR activation screens targeting lipid metabolic regulators within metastatic cancer cell populations. Their high-throughput approach illuminated acyl-CoA binding protein (ACBP) as a pivotal driver of bone metastasis. ACBP modulates lipid metabolism by promoting fatty acid oxidation (FAO), a metabolic process integral to energy homeostasis in tumor cells, while simultaneously mitigating lipid peroxidation and ferroptosis, thus conferring survival advantages in the hostile bone microenvironment. Ablation of ACBP in highly metastatic cancer cells robustly abrogated bone colonization in animal models. In tandem, pharmacological inhibition of FAO or induced ferroptosis effectively curtailed metastatic progression, underscoring ACBP and associated metabolic pathways as promising therapeutic targets for combating skeletal metastases.

Delving further into the epigenetic underpinnings of metastatic progression, the collaborative work of Drs. Chenling Meng, Yue Lu, and Di Zhao spotlighted the histone methyltransferase ASH1L as a critical regulator in advanced prostate cancer bone metastasis. Genomic analyses revealed frequent amplification and overexpression of ASH1L in multiple aggressive cancer types. Mechanistic studies demonstrated that ASH1L engages in direct interaction with the hypoxia-inducible factor HIF-1α, orchestrating the transcriptional reprogramming of pro-metastatic and lipid metabolism-related gene networks. This crosstalk induces a phenotypic switch in tumor-associated macrophages, promoting the emergence of lipid-laden, tumor-supportive macrophages that foster immune evasion and facilitate metastatic niche establishment. Intriguingly, pharmacologic blockade of the ASH1L-HIF-1α axis suppressed bone metastatic lesions, validating ASH1L as a promising epigenetic driver and therapeutic target in metastatic prostate cancer.

In a pivotal advancement for the treatment of multiple myeloma among elderly patients, MD Anderson researchers evaluated teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), within a cohort inclusive of those aged 75 and older. Although teclistamab was approved following the MajesTEC-1 study, older adults have historically been underrepresented in clinical trials. The team, under the leadership of Drs. Oren Pasvolsky and Hans Lee, performed a comprehensive real-world analysis on 385 relapsed/refractory multiple myeloma patients. Their findings revealed no significant differences in safety profiles, including incidence of cytokine release syndrome and neurotoxicity, nor in response rates and progression-free survival between older and younger groups. Notably, patients over 75 exhibited an overall response rate of 62% and extended progression-free survival relative to their younger counterparts. This evidence affirms teclistamab’s suitability as a safe and efficacious therapeutic option for elderly myeloma patients—a population often underserved by novel treatment paradigms.

Beyond these scientific breakthroughs, the MD Anderson community has celebrated landmark recognitions. Dr. James Allison, whose pioneering work in immunotherapy transformed oncology, alongside Dr. Padmanee Sharma, a leader in genitourinary medical oncology, were honored with the prestigious 2025 Ellis Island Medal of Honor. Additionally, Dr. Ronnie Sebro was bestowed the 2025 Imaging Informatics Innovator Award by the Society for Imaging Informatics in Medicine, highlighting the institution’s commitment to excellence across oncology disciplines.

Collectively, these studies underscore the multifaceted nature of cancer biology, incorporating genetic, epigenetic, metabolic, and immunologic dimensions. The dissection of disease mechanisms, such as immune evasion in sickle cell-associated cancers or metabolic rewiring in CRPC and bone metastases, provides fertile ground for innovative therapeutic design. Targeting ferroptosis dysregulation, exploiting lipid metabolic vulnerabilities, and reprogramming tumor microenvironments are emerging strategies poised to break through longstanding therapeutic resistance.

Importantly, the research reflects MD Anderson’s translational ethos—transforming molecular insights into tangible clinical solutions. By emphasizing biomarker-guided therapy, the center advances personalized medicine approaches, tailoring interventions based on patient-specific tumor profiles. The promising preclinical results combining cholesterol-lowering agents with hormone therapies exemplify this paradigm, demonstrating how precision oncology can combat cancer’s adaptive capacities.

Moreover, the evaluation of teclistamab in elderly populations addresses an essential unmet need in oncology—ensuring that cutting-edge therapies are accessible and effective across diverse patient demographics. Inclusive research that bridges clinical trial data and real-world outcomes enables optimized care strategies, improving survival and quality of life.

In conclusion, MD Anderson’s latest research highlights exemplify the accelerated pace of discovery in cancer biology and therapy development. By elucidating new drivers of treatment resistance and metastasis, and by validating innovative therapeutic approaches, these efforts hold the promise of improving outcomes for patients with some of the most challenging cancers. The integration of molecular biology, immunology, and metabolic science continues to revolutionize our understanding, providing a robust framework for the next generation of cancer treatments.

Subject of Research:
Cancer biology and therapy resistance, sickle cell disease impact on immunity, metastatic prostate cancer, bone metastasis mechanisms, multiple myeloma treatment in elderly patients.

Article Title:
MD Anderson Cancer Center Unveils New Insights into Cancer Immunity, Metastasis, and Therapeutics

News Publication Date:
May 21, 2025

Web References:

• MD Anderson Research Highlights
• Sickle Cell Disease and Immunity in Immunity
• Prostate Cancer Combination Therapy in Nature Cancer
• Bone Metastasis Driver in Science Translational Medicine
• Epigenetic Driver of Metastasis in Nature Communications
• Teclistamab Safety in Blood Cancer Journal

References:
Refer to the original peer-reviewed publications linked above for detailed experimental data and methodologies.

Keywords:
Cancer research, Sickle cell anemia, Cancer immunology, Bone cancer, Prostate cancer, Metastasis, Multiple myeloma

The immune system’s ability to recognize and eliminate cancer cells hinges on effective antigen presentation, a process primarily mediated by the human leukocyte antigen class I (HLA-I) complex. Tumor antigens are processed and presented on HLA-I molecules on the cancer cell surface, flagging aberrant cells for destruction by CD8+ cytotoxic T lymphocytes. Paradoxically, BCC cells suppress the expression of HLA-I, effectively cloaking themselves in immunological invisibility. This suppression results from a sophisticated epigenomic mechanism connected to the tumor’s cell of origin and its intrinsic stemness programs.

Dr. Demehri’s team meticulously compared BCC samples to cutaneous squamous cell carcinomas (SCCs), which exhibit higher responsiveness to immune checkpoint inhibitors. Through single-cell RNA sequencing and histological analyses, they demonstrated that BCCs harbor an "immune-excluded" microenvironment, characterized by minimal infiltration of CD4+ and CD8+ T cells within tumor foci. This contrasts sharply with SCCs, where immune cells readily penetrate the tumor stroma. The immune exclusion observed in BCC correlates tightly with the downregulation of antigen presentation machinery (APM), evident even at early disease stages, suggesting an inherent, developmental basis for immune evasion.

Central to this suppression is the transcription factor Foxc1, which is normally involved in maintaining quiescence of hair follicle stem cells — the presumptive cell of origin for BCC. Foxc1 directly represses genes encoding key components of the APM, including HLA-I and interferon regulatory factor 1 (IRF1), through epigenomic modifications that silence their expression. This pharmacologically reversible epigenetic repression provides a molecular explanation for why BCCs, despite their heavy mutational load, remain largely undetected and refractory to immune attack.

The clinical implications of these discoveries are profound. Dr. Demehri’s research shows that topical application of entinostat, a histone deacetylase inhibitor, can epigenetically reverse APM suppression in BCC cells in vivo. When used in combination with imiquimod, a topical immune response modifier approved for skin cancers, entinostat significantly enhances antigen presentation and stimulates immune cell infiltration, producing a synergistic antitumor effect. This dual-regimen effectively overcomes the immune exclusion barrier, transforming BCC from an immunologically "cold" tumor into one more amenable to immune-mediated clearance.

Such findings challenge the existing paradigm that high tumor mutational burden necessarily predicts immunotherapy success. Instead, they emphasize the pivotal role of a cancer’s cellular and epigenetic context, particularly the intrinsic stemness programs inherited from their cell of origin, in dictating immunogenicity. By targeting these epigenomic regulators, it may be possible to sensitize otherwise resistant tumors to immune-based treatments, broadening the therapeutic horizon beyond BCC.

Beyond immediate treatment strategies, this work raises critical questions about how tissue-specific stemness pathways modulate tumor-immune interactions more broadly. Could similar epigenetic constraints on antigen presentation operate in other cancers arising from quiescent stem cell populations? If so, unraveling these intrinsic immunosuppressive mechanisms may unlock new generalizable approaches to cancer immunotherapy.

Furthermore, these insights offer hope for organ transplant recipients and immunosuppressed patients, who are disproportionately susceptible to SCC yet relatively spared from BCC development. This differential risk underscores the clinical relevance of BCC’s low immunogenicity and may inform personalized surveillance and therapeutic strategies for high-risk populations.

In essence, this study elegantly combines molecular immunology, epigenomics, and clinical oncology to redefine our understanding of tumor immune evasion. The identification of Foxc1 as a master regulator of antigen presentation heralds a new chapter in skin cancer research and immunotherapy, anchored in the biology of the tumor’s origin rather than mutation burden alone.

Looking forward, Dr. Demehri and colleagues advocate for clinical trials testing the efficacy and safety of entinostat-primed immunotherapy in patients with BCC. Such trials could validate this novel combination as a frontline or adjunct treatment, potentially improving outcomes for thousands of patients afflicted with this common yet challenging cancer.

This research exemplifies the power of combining cutting-edge single-cell technologies with translational oncology to unravel the complex interplay between cancer cell states and immune recognition. As the field of cancer immunotherapy continues to evolve, studies like this underscore the importance of considering tumor cell origin and epigenetic regulation when designing effective treatments.

In conclusion, the elucidation of epigenomic mechanisms governing stemness and immune suppression opens promising avenues not only for the treatment of basal cell carcinoma but also for a broader understanding of cancer immunobiology. By leveraging these insights, the oncology community stands poised to overcome longstanding barriers in combating immune-resistant tumors, heralding a new era of precision medicine and immunotherapy.

Subject of Research: Cells

Article Title: Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer

News Publication Date: 17-Apr-2025

Web References:

• https://www.cell.com/cell-reports/fulltext/S2211-1247(25)00332-8
• http://dx.doi.org/10.1016/j.celrep.2025.115561

Image Credits: Shawn Demehri, Massachusetts General Hospital

Keywords: Skin cells, Immunogenicity, Combination therapies, Cancer immunotherapy